MindBio Therapeutics CorpCanadian Securities Exchange:MBIO
- LAST PRICE0.0650
- TODAY'S CHANGE (%)0.0100 (18.1818%)
- Bid / Lots0.0550/ 40
- Ask / Lots0.0700/ 25
- Open / Previous Close0.0550 / 0.0550
- Day Range
- 52 Week Range
- Volume14,112
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MBIO |
|---|---|---|
| 09:43 ET | 11000 | 0.055 |
| 02:51 ET | 2000 | 0.065 |
Today
Apr 23, 2024
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry, from 12:22AM ET on Tuesday Apr 23, 2024 by Dow Jones
12:22AM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 16, 2024
Lender Requests to Convert Loan to MindBio Shares, from 6:40AM ET on Tuesday Apr 16, 2024 by Dow Jones
6:40AM ET on Tuesday Apr 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MindBio Therapeutics Corp | 7.5M | -2.1x | --- |
Voyageur Pharmaceuticals Ltd | 6.9M | -5.5x | --- |
Blueberries Medical Corp | 6.0M | -2.6x | --- |
Bhang Inc | 5.1M | -0.7x | --- |
Intellipharmaceutics International Inc | 2.6M | -0.6x | --- |
Mojave Brands Inc | 3.0M | -2.4x | --- |
Company Information
MindBio Therapeutics Corp. is a biotechnology company. The Company is focused on creating novel and emerging treatments for mental health conditions and is conducting lysergic acid diethylamide (LSD)-microdosing human clinical trials. It has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development. It has completed Phase I clinical trials microdosing LSD in 80 patients, has a Phase II clinical trial in development microdosing LSD in patients with major depressive disorder, and has a Phase II clinical trial in development microdosing LSD in late-stage cancer patients experiencing existential distress. The Company invests in research that forms the basis for developing novel and clinically proven treatments, including digital technologies and interventions, to treat debilitating health conditions such as depression, anxiety, and other related mental health conditions.
Contact Information
- Headquarters
- 1055 West Georgia Street 1500 Royal CentreVANCOUVER, BC, Canada V6E 4N7
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.5M |
|---|---|
Revenue (TTM) | $177.1K |
Shares Outstanding | 135.0M |
MindBio Therapeutics Corp does not pay a dividend. | |
Beta | --- |
EPS | $-0.03 |
Book Value | $-0.04 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 42.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,704.10% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
